Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Activon Co. Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned across 4 examiners and 4 art units, which indicates that each pending matter has a distinct examiner and art-unit assignment in the reported data.
FERNANDEZ, SUSAN EMILY is the busiest examiner with 1 pending matter. The equal distribution provides no evidence of concentration around a single examiner. Response preparation can consequently focus on matter-specific prosecution issues and the requirements of each assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
| GAMBETTA, KELLY M | 1 | 71.8% | +33.0% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287504 | LACTOBACILLUS REUTERI JH53 STRAIN HAVING EXCELLENT ORGANIC ACID RESISTANCE AND CONVERSION OF 1,3-PROPANDIOL FROM GLYCEROL, AND USE THEREOF | FERNANDEZ, SUSAN EMILY | — |
| 18712901 | INK COMPOSITION FOR SURFACE PRINTING ON COSMETICS, AND METHOD FOR SURFACE PRINTING ON COSMETICS BY USING SAME | GAMBETTA, KELLY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287504 | LACTOBACILLUS REUTERI JH53 STRAIN HAVING EXCELLENT ORGANIC ACID RESISTANCE AND CONVERSION OF 1,3-PROPANDIOL FROM GLYCEROL, AND USE THEREOF | FERNANDEZ, SUSAN EMILY | — |
| 18712901 | INK COMPOSITION FOR SURFACE PRINTING ON COSMETICS, AND METHOD FOR SURFACE PRINTING ON COSMETICS BY USING SAME | GAMBETTA, KELLY M | — |
| 18690763 | ALTERNATIVE NOVEL MATERIAL TO BOTULINUM NEUROTOXIN AND PREPARATION METHOD THEREOF | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1718 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287504 | LACTOBACILLUS REUTERI JH53 STRAIN HAVING EXCELLENT ORGANIC ACID RESISTANCE AND CONVERSION OF 1,3-PROPANDIOL FROM GLYCEROL, AND USE THEREOF | FERNANDEZ, SUSAN EMILY | 1651 | §102§112 | Non-Final OA | — | Pending | Jan 27, 2025 |
| 18712901 | INK COMPOSITION FOR SURFACE PRINTING ON COSMETICS, AND METHOD FOR SURFACE PRINTING ON COSMETICS BY USING SAME | GAMBETTA, KELLY M | 1718 | §103§112 | Final Rejection | — | Pending | May 23, 2024 |
| 18690763 | ALTERNATIVE NOVEL MATERIAL TO BOTULINUM NEUROTOXIN AND PREPARATION METHOD THEREOF | GONZALEZ, LUISALBERTO | 1624 | §112 | Final Rejection | — | Pending | Mar 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialActivon Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Susan Emily Fernandez has the most, with 1 of Activon Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
